The research company Chosa Oncology reports, as planned, no revenue in the fourth quarter. The operating loss decreased.The operating result was SEK -0.1 million (-0.3). The result before tax was SEK -0.3 million (-0.2). The result after tax was SEK 0.7 million (0.5).Cash flow from operating activities amounted to SEK 3.8 million (0.5). Cash and cash equivalents amounted to SEK 1.8 million (6.4)."To support our continued development and commercialization strategy, Chosa carried out a directed issue of units that provided the company with approximately SEK 7.3 million before transaction costs. The capital strengthens our balance sheet and enables us to maintain momentum inregulatory preparations, partnership discussions, as well as continued clinical and analytical validation," comments CEO Peter Buhl Jensen.The head of Chosa also states in the report that, thanks to a strengthened intellectual property position and a broadened market opportunity, the company is deemed to be entering a new phase of value creation.Chosa Oncology, SEK mQ4-2025Q4-2024ChangeNet sales00Operating result-0.1-0.3Result before tax-0.3-0.2Net income0.70.540.0%Cash flow from operating activities3.80.5660.0%Cash and cash equivalents1.86.4-71.9%